Dr Adrian Blaser

MSc PhD Bern

Biography

Adrian Blaser obtained his Masters and PhD in Chemistry from the University of Bern, Switzerland. After a postdoctoral position with Professor Margaret Brimble at the University of Auckland, Adrian was appointed as a Research Fellow in the Centre designing and developing novel drugs for cancer treatment.

Research interests

Research | Current

After 3 years on a variety of projects ranging from developing a backup compound for a drug in clinical trial phase I on erbB2 Inhibition to developing a new Antibacterial agent I am now working on a project in collaboration with the Global Alliance of Tuberculosis (GATB) to develop a backup drug of PA-824, a new antibacterial agent against Mycobacterium tuberculosis. The aim of the project is to develop an efficient drug with a novel mode of action that avoids cross-resistance with existing drugs, and will simultaneously address many pressing current medical needs.

I am now in charge of the NMR facility at the ACSRC.

Selected publications and creative works (Research Outputs)

  • Black, S. L., O'Connor PD, Boyd, M., Blaser, A., & Kendall, J. D. (2018). Synthesis and H-1, C-13 and N-15 NMR characterisation of substituted Pyrazolo[4,3-c]quinolines and related compounds. TETRAHEDRON, 74 (22), 2797-2806. 10.1016/j.tet.2018.04.061
  • Sutherland, H. S., Tong, A. S. T., Choi, P. J., Conole, D., Blaser, A., Franzblau, S. G., ... Denny, W. A. (2018). Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorganic & medicinal chemistry, 26 (8), 1797-1809. 10.1016/j.bmc.2018.02.026
    Other University of Auckland co-authors: Peter Choi, Bill Denny, Brian Palmer, Hamish Sutherland
  • Thompson, A. M., O'Connor PD, Marshall, A. J., Blaser, A., Yardley, V., Maes, L., ... Chatelain, E. (2018). Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of medicinal chemistry, 61 (6), 2329-2352. 10.1021/acs.jmedchem.7b01581
    Other University of Auckland co-authors: Andrew Thompson, Bill Denny
  • Choi, P. J., Sutherland, H. S., Tong, A. S., Blaser, A., Franzblau, S. G., Cooper, C. B., ... Motte, M. (2017). Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorganic and Medicinal Chemistry Letters, 27 (23), 5190-5196. 10.1016/j.bmcl.2017.10.042
    Other University of Auckland co-authors: Hamish Sutherland, Peter Choi, Bill Denny, Brian Palmer
  • Tong, A. S., Choi, P. J., Blaser, A., Sutherland, H. S., Tsang, S. K., Guillemont, J., ... Van den Broeck, W. (2017). 6-cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis. ACS Medicinal Chemistry Letters, 8 (10), 1019-1024. 10.1021/acsmedchemlett.7b00196
    Other University of Auckland co-authors: Peter Choi, Hamish Sutherland, Bill Denny, Brian Palmer
  • Choi, P. J., Tong, S. T., Denny, W. A., Palmer, B. D., Blaser, A., Conole, D., ... Upton, A. M. (7/9/2017). Synthetic studies towards the development of less lipophilic drug of bedaquiline. Poster presented at Queenstown Research Week, Rydges Hotel, Queenstown, New Zealand. National Symposium on Infectious Diseases: key opportunities and emerging therapies.
    Other University of Auckland co-authors: Peter Choi, Bill Denny, Brian Palmer, Hamish Sutherland
  • Thompson, A., Blaser, A., Palmer, B., Anderson, R., Shinde, S., Launay, D., ... Wan, B. (2017). 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic and Medicinal Chemistry Letters, 27 (11), 2583-2589. 10.1016/j.bmcl.2017.03.069
    URL: http://hdl.handle.net/2292/34389
    Other University of Auckland co-authors: Brian Palmer, Andrew Thompson, Bob Anderson, Bill Denny
  • Smaill, J., Gonzales, A., Spicer, J., Lee, H., Reed, J., Sexton, K., ... Blaser, A. (2016). Tyrosine kinase inhibitors. 20. optimization of substituted quinazoline and pyrido[3,4- d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family. Journal of Medicinal Chemistry, 59 (17), 8103-8124. 10.1021/acs.jmedchem.6b00883
    URL: http://hdl.handle.net/2292/32487
    Other University of Auckland co-authors: Jeffrey Smaill, Bill Denny, Andrew Thompson, Julie Spicer, Brian Palmer

Identifiers

Contact details

Alternative contact

DDI +64 9 923 8228

Mobile +64 21 232 7998

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 1, Room 125
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand

Web links